// App-Quantinova.ai

2836 : Preclinical Development of AT1412, a Patient Derived CD9 Antibody That Does Not Induce Thrombosis for Treatment of B ALL

Researchers

Presenter

  • Remko Schotte

Principal Investigators

  • Greta De Jong

  • Viviana Neviani

  • Wouter Pos

  • Sophie E Levie

  • Daniel M Go

  • Etsuko Yasuda

  • Esmay Frankin

  • Madalina Cercel

  • Susan E van Hal-van Veen

  • Dorien van de Berg

  • Anik Szab

  • Christien Fatmawati

  • Martijn Kedde

  • Yvonne Claassen

  • Sjeng Horbach

  • Anita W Rijneveld

  • Piet Gros

  • Hergen Spits

  • Mette D Hazenberg

  • Hans van Eenennaam

Medical Centers

  • AIMM Therapeutics, Amsterdam, Netherlands

  • Department of Hematology, VU Medical Center, Amsterdam, Netherlands

  • Utrecht University, Utrecht, NLD

  • Department of Medical Oncology, VU University Medical Center, Amsterdam, Netherlands

  • Sjeng Horbach Consultancy, Oss, Netherlands

  • Utrecht University, Utrecht, Netherlands

  • Amsterdam Infection and Immunity Institute, Amsterdam, Netherlands

  • Academic Medical Center, Amsterdam, Netherlands

  • Department of Hematology, Amsterdam UMC, Academic Medical Center, Amsterdam, Netherlands

Locations

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B-cell acute lymphoblastic leukemia

  • Acute lymphoblastic leukemia

  • Melanoma

  • Thrombocytopenia

  • Solid malignancies

  • Venous thrombosis

  • T-cell acute lymphoblastic leukemia

Biomarkers

  • Aldo-keto Reductase Family 1 Member B10

  • Cluster of Differentiation 14

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

Drug/Treatment

  • Interferon alpha

  • Blinatumomab

  • Mitoxantrone

  • Cytarabine liposomal

  • Interferon

  • Immunol

Outcome

  • N/A

Study Design

  • First-In-Human

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved